Compare Lupin with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs JUBILANT PHARMOVA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN JUBILANT PHARMOVA LUPIN/
JUBILANT PHARMOVA
 
P/E (TTM) x 42.4 14.0 302.3% View Chart
P/BV x 3.9 2.6 148.8% View Chart
Dividend Yield % 0.6 0.6 97.7%  

Financials

 LUPIN   JUBILANT PHARMOVA
EQUITY SHARE DATA
    LUPIN
Mar-20
JUBILANT PHARMOVA
Mar-19
LUPIN/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs882898 98.2%   
Low Rs505618 81.8%   
Sales per share (Unadj.) Rs339.4572.0 59.3%  
Earnings per share (Unadj.) Rs-5.936.2 -16.4%  
Cash flow per share (Unadj.) Rs15.559.5 26.0%  
Dividends per share (Unadj.) Rs6.004.50 133.3%  
Dividend yield (eoy) %0.90.6 145.7%  
Book value per share (Unadj.) Rs276.7301.9 91.7%  
Shares outstanding (eoy) m453.00159.28 284.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.3 154.3%   
Avg P/E ratio x-116.620.9 -557.6%  
P/CF ratio (eoy) x44.812.7 352.1%  
Price / Book Value ratio x2.52.5 99.9%  
Dividend payout %-100.912.4 -812.2%   
Avg Mkt Cap Rs m314,201120,694 260.3%   
No. of employees `00018.32.4 765.8%   
Total wages/salary Rs m29,86819,260 155.1%   
Avg. sales/employee Rs Th8,400.638,120.6 22.0%   
Avg. wages/employee Rs Th1,632.08,058.4 20.3%   
Avg. net profit/employee Rs Th-147.22,414.3 -6.1%   
INCOME DATA
Net Sales Rs m153,74891,108 168.8%  
Other income Rs m4,838357 1,353.6%   
Total revenues Rs m158,58591,466 173.4%   
Gross profit Rs m24,84917,390 142.9%  
Depreciation Rs m9,7023,709 261.6%   
Interest Rs m3,6302,198 165.1%   
Profit before tax Rs m16,35511,840 138.1%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,521-2,802 268.4%   
Tax Rs m11,5713,268 354.1%   
Profit after tax Rs m-2,6945,770 -46.7%  
Gross profit margin %16.219.1 84.7%  
Effective tax rate %70.827.6 256.3%   
Net profit margin %-1.86.3 -27.7%  
BALANCE SHEET DATA
Current assets Rs m154,13245,848 336.2%   
Current liabilities Rs m92,25220,897 441.5%   
Net working cap to sales %40.227.4 147.0%  
Current ratio x1.72.2 76.2%  
Inventory Days Days8257 144.5%  
Debtors Days Days12951 253.8%  
Net fixed assets Rs m89,08265,498 136.0%   
Share capital Rs m906159 568.7%   
"Free" reserves Rs m124,46147,930 259.7%   
Net worth Rs m125,36748,089 260.7%   
Long term debt Rs m17,93342,429 42.3%   
Total assets Rs m249,839114,685 217.8%  
Interest coverage x5.56.4 86.2%   
Debt to equity ratio x0.10.9 16.2%  
Sales to assets ratio x0.60.8 77.5%   
Return on assets %0.46.9 5.4%  
Return on equity %-2.112.0 -17.9%  
Return on capital %8.712.4 70.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45012,422 414.2%   
Fx outflow Rs m19,47017,227 113.0%   
Net fx Rs m31,980-4,805 -665.6%   
CASH FLOW
From Operations Rs m14,68811,215 131.0%  
From Investments Rs m11,070-10,118 -109.4%  
From Financial Activity Rs m-8,9066,574 -135.5%  
Net Cashflow Rs m16,8537,612 221.4%  

Share Holding

Indian Promoters % 46.6 45.6 102.2%  
Foreign collaborators % 0.2 3.5 5.7%  
Indian inst/Mut Fund % 11.3 8.7 129.9%  
FIIs % 31.9 21.2 150.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.1 47.9%  
Shareholders   98,259 23,815 412.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   SANOFI INDIA  ABBOTT INDIA  DISHMAN PHARMA  CIPLA  ASTRAZENECA PHARMA  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 202 Points Lower; Britannia and Mahindra & Mahindra Among Top Nifty Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Apr 23, 2021 (Close)

TRACK LUPIN

LUPIN - TORRENT PHARMA COMPARISON

COMPARE LUPIN WITH

MARKET STATS